Basal and postprandial plasma levels of PYY, ghrelin, cholecystokinin, gastrin and insulin in women with moderate and morbid obesity and metabolic syndrome.
暂无分享,去创建一个
J. Rehfeld | T. Brzozowski | P. Sowa | M. Kukla | M. Wylezol | K. Żwirska-Korczala | A. Berdowska | M. Adamczyk-Sowa | W. Bielański | S. Konturek | Konturek Sj | D. Kuka | M. Sodowski | P. Sowa
[1] J. H. Peters,et al. Modulation of vagal afferent excitation and reduction of food intake by leptin and cholecystokinin , 2006, Physiology & Behavior.
[2] Norbert Bannert,et al. Peripheral injection of ghrelin induces Fos expression in the dorsomedial hypothalamic nucleus in rats , 2006, Brain Research.
[3] D. Cummings. Ghrelin and the short- and long-term regulation of appetite and body weight , 2006, Physiology & Behavior.
[4] Jia-Yi Li,et al. Neuropeptide Y2 receptors are involved in enhanced neurogenic vasoconstriction in spontaneously hypertensive rats , 2006, British journal of pharmacology.
[5] M. Päivänsalo,et al. Plasma ghrelin concentrations are positively associated with carotid artery atherosclerosis in males , 2006, Journal of internal medicine.
[6] P. Holvoet,et al. Human Paraoxonase-1 Overexpression Inhibits Atherosclerosis in a Mouse Model of Metabolic Syndrome , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[7] Y. Dong,et al. Regulative effects of ovarian steroids on rat gastric motility and sensitivity. , 2006, Sheng li xue bao : [Acta physiologica Sinica].
[8] M. Jensen. Potential Role of New Therapies in Modifying Cardiovascular Risk in Overweight Patients with Metabolic Risk Factors , 2006, Obesity.
[9] U. Müller-Ladner,et al. Role of adipose tissue as an inflammatory organ in human diseases. , 2006, Endocrine reviews.
[10] J. Rehfeld. The endoproteolytic maturation of progastrin and procholecystokinin , 2006, Journal of Molecular Medicine.
[11] J. Meigs. Definitions and mechanisms of the metabolic syndrome , 2006 .
[12] J. Wishart,et al. Effects of load, and duration, of duodenal lipid on antropyloroduodenal motility, plasma CCK and PYY, and energy intake in healthy men. , 2006, American journal of physiology. Regulatory, integrative and comparative physiology.
[13] L. Lind,et al. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study , 2006, BMJ : British Medical Journal.
[14] Paul Poirier,et al. Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss: An Update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease From the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism , 2006, Circulation.
[15] J. Olefsky,et al. Inflamed fat: what starts the fire? , 2005, The Journal of clinical investigation.
[16] P. Konturek,et al. Neuro-hormonal control of food intake: basic mechanisms and clinical implications. , 2005, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.
[17] M. Wylezol,et al. Bariatric surgery in Poland from 1993 to 2003. , 2005, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.
[18] R. D'Agostino,et al. Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus , 2005, Circulation.
[19] Christoph Beglinger,et al. Effect of peptide YY3-36 on food intake in humans. , 2005, Gastroenterology.
[20] D. Allison,et al. PYY3‐36 as an anti‐obesity drug target , 2005, Obesity reviews : an official journal of the International Association for the Study of Obesity.
[21] T. Peeters,et al. Ghrelin: a new player in the control of gastrointestinal functions , 2005, Gut.
[22] K. Toshinai,et al. The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats. , 2005, Endocrinology.
[23] S. Bloom,et al. Ghrelin, peptide YY, glucose-dependent insulinotropic polypeptide, and hunger responses to a mixed meal in anorexic, obese, and control female adolescents. , 2005, The Journal of clinical endocrinology and metabolism.
[24] G. Pacini,et al. Islet adaptation to insulin resistance: mechanisms and implications for intervention , 2005, Diabetes, obesity & metabolism.
[25] M. Nakazato,et al. Altered ghrelin and peptide YY responses to meals in bulimia nervosa , 2005, Clinical endocrinology.
[26] M. Fujimiya,et al. Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin , 2004, Gut.
[27] R. Ahima,et al. Gut peptides and other regulators in obesity. , 2004, Seminars in liver disease.
[28] B. Draznin,et al. Molecular mechanisms of insulin resistance that impact cardiovascular biology. , 2004, Diabetes.
[29] E. Arvat,et al. Ghrelin secretion is inhibited by glucose load and insulin‐induced hypoglycaemia but unaffected by glucagon and arginine in humans , 2004, Clinical endocrinology.
[30] R. Silverstein,et al. Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study. , 2004, The Biochemical journal.
[31] H. Pijl,et al. PYY3-36 reinforces insulin action on glucose disposal in mice fed a high-fat diet. , 2004, Diabetes.
[32] K. Wynne,et al. Gastrointestinal satiety signals III. Glucagon-like peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide. , 2004, American journal of physiology. Gastrointestinal and liver physiology.
[33] M. Korbonits,et al. Ghrelin—a hormone with multiple functions , 2004, Frontiers in Neuroendocrinology.
[34] J. Konturek,et al. Brain-gut axis and its role in the control of food intake. , 2004, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.
[35] B. Beck,et al. Ghrelin and Body Weight Regulation in the Obese Zucker Rat in Relation to Feeding State and Dark/Light Cycle , 2003, Experimental biology and medicine.
[36] Mohammad A Ghatei,et al. Inhibition of food intake in obese subjects by peptide YY3-36. , 2003, The New England journal of medicine.
[37] K. Nin,et al. Plasma levels of active form of ghrelin during oral glucose tolerance test in patients with anorexia nervosa. , 2003, European journal of endocrinology.
[38] E. Ford. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. , 2003, Atherosclerosis.
[39] C. Ronchi,et al. Stimulatory effects of ghrelin on circulating somatostatin and pancreatic polypeptide levels. , 2003, The Journal of clinical endocrinology and metabolism.
[40] R. Jensen,et al. Involvement of cholecystokinin/gastrin-related peptides and their receptors in clinical gastrointestinal disorders. , 2002, Pharmacology & toxicology.
[41] K. Kangawa,et al. Fasting plasma ghrelin levels are negatively correlated with insulin resistance and PAI-1, but not with leptin, in obese children and adolescents. , 2002, Diabetes.
[42] Rachel L. Batterham,et al. Gut hormone PYY3-36 physiologically inhibits food intake , 2002, Nature.
[43] J. Yudkin,et al. The central roles of obesity-associated dyslipidaemia, endothelial activation and cytokines in the Metabolic Syndrome—an analysis by structural equation modelling , 2002, International Journal of Obesity.
[44] Márta Korbonits,et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. , 2002, The Journal of clinical endocrinology and metabolism.
[45] S. Bloom,et al. Food fails to suppress ghrelin levels in obese humans. , 2002, The Journal of clinical endocrinology and metabolism.
[46] J. A. Fernández-Represa,et al. Peptide YY Secretion in Morbidly Obese Patients Before and After Vertical Banded Gastroplasty , 2002, Obesity surgery.
[47] G. Schwartz,et al. Responsivity to NPY and melanocortins in obese OLETF rats lacking CCK-A receptors , 2002, Physiology & Behavior.
[48] M. Mulholland,et al. Inhibition of pancreatic protein secretion by ghrelin in the rat , 2001, The Journal of physiology.
[49] T. Koh,et al. Gastrin as a growth factor in the gastrointestinal tract , 2000, Regulatory Peptides.
[50] C. Beglinger,et al. Two molecular forms of Peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1–36 and PYY 3–36 , 1994, Regulatory Peptides.
[51] T. Brewerton,et al. CSF cholecystokinin octapeptide in patients with bulimia nervosa and in normal comparison subjects. , 1993, The American journal of psychiatry.
[52] N. Read,et al. Preliminary studies on the gastrointestinal responses to fatty meals in obese people. , 1993, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.
[53] R. Turner,et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.
[54] J. H. Payne,et al. Surgical treatment of obesity. , 1969, American journal of surgery.
[55] K. Wynne,et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. , 2006, Endocrinology.
[56] G. Dockray,et al. Gastrin: old hormone, new functions , 2004, Pflügers Archiv.
[57] C. Dina,et al. Genetic, pharmacological and functional analysis of cholecystokinin-1 and cholecystokinin-2 receptor polymorphism in type 2 diabetes and obese patients. , 2002, Pharmacogenetics.